<DOC>
	<DOC>NCT00480571</DOC>
	<brief_summary>An open-label, multi-center, 6-week, sequential cohort study designed to determine the safety and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic schizophrenia or schizo-affective disorder</brief_summary>
	<brief_title>Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<criteria>Male or female 18 to 65 years of age, inclusive meet criteria for chronic (diagnosis established &gt; 1 year ago) schizophrenia with adequate psychotic symptoms as demonstrated by a PANSS total score &gt; 60 current diagnosis of schizophrenia (disorganized type, 295.10; catatonic type, 295.20; paranoid type, 295.30; undifferentiated type, 295.90) or schizoaffective disorder (295.7) in accordance with DSMIV Agree to be fully hospitalized until at least Day 14 of the study Females must be of nonchildbearing potential: surgically sterilized (i.e. tubal ligation), have had a hysterectomy prior to the screening phase, or be postmenopausal. Females who have been postmenopausal for more than 12 months but less than 24 months must have a FSH &gt; 40 mU/mL. Pregnant or lactating women administration of clozapine within 60 days prior to Baseline DSMIV diagnosis of schizophreniform disorder (295.40) or schizophrenia residual subtype (295.60), or other primary psychiatric diagnoses, such as bipolar disorder or major depressive disorder Severity of psychosis rated severe or higher (CGIS 6 or 7) Known suicidal risk (modified ISST score&gt;7) Requiring disallowed concomitant psychotropic medication following enrolment into the study Current evidence of clinically significant or unstable illness Clinically significant abnormal laboratory data (e.g. creatinine, AST or ALT greater than 3 x the upper limit of normal, TSH&gt;10 IU) at screening, or any abnormal laboratory values that could interfere with the assessment of safety (e.g. blood cell count, etc.).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>chronic schizophrenia or schizo-affective disorder</keyword>
</DOC>